11 January 2017 - The guidance relates to the use of Keytruda (pembrolizumab) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.

Pembrolizumab is recommended as an option for treating locally advanced or metastatic PD‑L1‑positive non‑small‑cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor  or anaplastic lymphoma kinase positive tumour), only if:

• Pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and
  
• Merck/MSD provides pembrolizumab with the discount agreed in the patient access scheme revised in the context of this appraisal.
  

Read NICE final guidance